TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:48
Celcuity Inc. ( CELC ) https://www.celcuity.com
13.08USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-10.47%
CELC
SPY
32.66%
CELC
3.24%
SPY
108.59%
CELC
32.66%
SPY
302.52%
CELC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
559.73
392.60
0.22
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.96
2437.35
3.74
-13.60
0.00
-3.68
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-9794.92
-12.87
-11623.01
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.552
-403.01
-61.82
1.15
Other Earnings and Cash Flow Stats:
Celcuity Inc. ( CELC ) Net Income TTM ($MM) is -93.97
Celcuity Inc. ( CELC ) Operating Income TTM ($MM) is -96.57
Celcuity Inc. ( CELC ) Owners' Earnings Annual ($MM) is 0.00
Celcuity Inc. ( CELC ) Current Price to Owners' Earnings ratio is 0.00
Celcuity Inc. ( CELC ) EBITDA TTM ($MM) is -96.44
Celcuity Inc. ( CELC ) EBITDA Margin is -11623.01%
Capital Allocation:
Celcuity Inc. ( CELC ) has paid 0.00 dividends per share and bought back -20.675421 million shares in the past 12 months
Celcuity Inc. ( CELC ) has increased its debt by 59.581915 million USD in the last 12 months
Capital Structure:
Celcuity Inc. ( CELC ) Interest-bearing Debt ($MM) as of last quarter is 96
Celcuity Inc. ( CELC ) Annual Working Capital Investments ($MM) are -12
Celcuity Inc. ( CELC ) Book Value ($MM) as of last quarter is 149
Celcuity Inc. ( CELC ) Debt/Capital as of last quarter is 64%
Other Balance Sheet Stats:
Celcuity Inc. ( CELC ) has 12 million in cash on hand as of last quarter
Celcuity Inc. ( CELC ) has 26 million of liabilities due within 12 months, and long term debt 96 as of last quarter
Celcuity Inc. ( CELC ) has 42 common shares outstanding as of last quarter
Celcuity Inc. ( CELC ) has 0 million USD of preferred stock value
Academic Scores:
Celcuity Inc. ( CELC ) Altman Z-Score is 1.31 as of last quarter
Celcuity Inc. ( CELC ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Celcuity Inc. ( CELC ) largest shareholder is owning shares at 0.00 ($MM) value
Buller Richard E(an insider) Sold 350 shares of Celcuity Inc. ( CELC ) for the amount of $5687.50 on 2024-10-23
13.05% of Celcuity Inc. ( CELC ) is held by insiders, and 81.47% is held by institutions
Celcuity Inc. ( CELC ) went public on 2017-09-20
Other Celcuity Inc. ( CELC ) financial metrics:
FCF:-74.47
Unlevered Free Cash Flow:0.00
EPS:-2.78
Operating Margin:-9794.92
Gross Profit Margin:-12.87
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-79.60
Beta:1.15
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Celcuity Inc. ( CELC ) :
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.